About us

Affimed: Harnessing innate and adaptive immunity to fight cancer

Corporate Presentation ROCK® Fact Sheet

New therapeutic options providing a long-term benefit or even a cure are needed for effective cancer treatment, while also reducing severe side effects. Affimed aims to address these challenges by redirecting immune cells with multi-specific antibodies to achieve optimized killing of malignant cells.

Leveraging our modular and versatile ROCK® (Redirected Optimized Cell Killing) platform, we generate proprietary, next-generation bispecific antibodies. Our tetravalent (four binding sites) bispecific (two targets) immune cell engagers have the ability to bring NK cells or T cells into proximity to cancer cells and trigger a signal cascade that leads to the destruction these cancer cells.

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

We believe that our product candidates, alone or in combination with other agents (e.g. checkpoint modulators, adoptive NK cells or cytokines), may ultimately improve clinical outcomes in cancer patients and could eventually become a key element of modern targeted oncology care.

Affimed was founded in 2000 based on technology developed by the group led by Professor Melvyn Little at Deutsches Krebsforschungszentrum, the German Cancer Research Center, or DKFZ, in Heidelberg. In 2009, Affimed set up its wholly owned unit AbCheck in Pilsen, Czech Republic, which focuses on fully human antibody screening and optimization.

Affimed in short

Our mission at Affimed is to create novel therapeutic options for patients suffering from cancer and other life-threatening diseases. With our differentiated approach to arming the body’s innate and adaptive immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.

Affimed’s proprietary ROCK® platform

We have used our extensive drug development expertise to generate antibody candidates tailored to different indications, leveraging our proprietary ROCK® platform. ROCK® enables generation of antibodies with the potential for competitive advantages over traditional therapies including highly customizable antibody engagers for tailored treatment options and generation of antibodies with variable pharmacokinetic (PK) profiles.

learn more about our approach

Our Pipeline

Diverse pipeline of differentiated and versatile engagers to activate innate and adaptive immunity

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

learn more about our pipeline

NK Cell Engagers

AFM13

Disease Target CD30Immune Cell Target CD16A
Hodgkin lymphoma + PD-1
Phase 1
Hodgkin lymphoma
Phase 2
Hodgkin lymphoma + adoptive NK cells
Pre-IND
CD30-positive lymphoma
Phase 2

AFM24

Disease Target EGFRwtImmune Cell Target CD16A
Solid tumors
Pre-IND

AFM26

Disease Target BCMAImmune Cell Target CD16A
Multiple Myeloma
Pre-IND
Affimed programs
Partnered programs

T Cell Engagers

AFM11

Disease Target CD19Immune Cell Target CD3
Non-Hodgkin lymphoma
Phase 1
Acute lymphocytic leukemia
Phase 1

AMV564 (Amphivena*)

Disease Target CD33Immune Cell Target CD3
Acute myeloid leukemia
Phase 1
Affimed programs
Partnered programs

*AMV564 originates from Affimed’s ROCK® platform.

Collaborations

Affimed fosters and continues to seek partnerships that are in line with the company’s overall corporate strategy to continue to move its clinical programs forward, enhance the development of Affimed’s internal pipeline and to allow for the technological advancement of our platform to realize the full potential of innate immune cells in oncology.

learn more about our partners

Management Team

Learn more about our experienced Management Team with a proven track record in biotech, pharma, product development and finance.

Management

Supervisory Board

Learn more about our Supervisory Board comprised of seasoned experts from the pharmaceutical and biotech industry.

Supervisory Board

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay